<DOC>
<DOCNO>EP-0658553</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Polycyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3121	A61K31341	A61K830	A61K31381	A61K31185	C07D33338	C07C6517	A61K3138	A61K3144	A61K3134	A61K800	A61K800	A61K3138	C07C6992	C07C6349	C07D33314	A61P1100	A61P900	A61K31455	A61K833	A61P2702	C07D30700	A61K849	C07D21370	C07C6300	A61Q500	C07D21380	A61K3140	A61P2900	A61K31185	A61K3144	C07C6524	A61K842	A61K314418	A61K3134	C07D20700	C07D21379	C07D21328	C07C6900	A61K3140	C07C6526	C07D21324	A61K830	C07C6528	A61P2900	C07C6984	C07D33316	C07D33340	A61K31235	C07D33334	A61K846	C07D21300	C07D30738	A61K864	A61P900	C07D21381	A61P2700	C07D20732	A61K31381	C07D21363	A61Q1908	A61P1700	A61K844	C07C6994	C07D20734	A61Q500	C07D20736	C07C6370	A61K314418	A61P1700	A61Q1908	A61K31341	C07D30768	A61K31455	A61K834	C07C65105	A61P1100	C07D30764	C07C6988	C07D33332	C07D30758	C07C6900	C07D33300	C07C6500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	C07D	C07C	A61K	A61K	A61K	A61K	A61K	A61K	C07C	C07C	C07D	A61P	A61P	A61K	A61K	A61P	C07D	A61K	C07D	C07C	A61Q	C07D	A61K	A61P	A61K	A61K	C07C	A61K	A61K	A61K	C07D	C07D	C07D	C07C	A61K	C07C	C07D	A61K	C07C	A61P	C07C	C07D	C07D	A61K	C07D	A61K	C07D	C07D	A61K	A61P	C07D	A61P	C07D	A61K	C07D	A61Q	A61P	A61K	C07C	C07D	A61Q	C07D	C07C	A61K	A61P	A61Q	A61K	C07D	A61K	A61K	C07C	A61P	C07D	C07C	C07D	C07D	C07C	C07D	C07C	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K8	A61K31	A61K31	C07D333	C07C65	A61K31	A61K31	A61K31	A61K8	A61K8	A61K31	C07C69	C07C63	C07D333	A61P11	A61P9	A61K31	A61K8	A61P27	C07D307	A61K8	C07D213	C07C63	A61Q5	C07D213	A61K31	A61P29	A61K31	A61K31	C07C65	A61K8	A61K31	A61K31	C07D207	C07D213	C07D213	C07C69	A61K31	C07C65	C07D213	A61K8	C07C65	A61P29	C07C69	C07D333	C07D333	A61K31	C07D333	A61K8	C07D213	C07D307	A61K8	A61P9	C07D213	A61P27	C07D207	A61K31	C07D213	A61Q19	A61P17	A61K8	C07C69	C07D207	A61Q5	C07D207	C07C63	A61K31	A61P17	A61Q19	A61K31	C07D307	A61K31	A61K8	C07C65	A61P11	C07D307	C07C69	C07D333	C07D307	C07C69	C07D333	C07C65	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to new polycyclic aromatic compounds of general formula (I): 
<
IMAGE
>
 and to the use of the latter in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological conditions, in particular) or alternatively in cosmetic compositions.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
CIRD GALDERMA
</APPLICANT-NAME>
<APPLICANT-NAME>
CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA)
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BERNARDON JEAN-MICHEL
</INVENTOR-NAME>
<INVENTOR-NAME>
CHARPENTIER BRUNO
</INVENTOR-NAME>
<INVENTOR-NAME>
BERNARDON, JEAN-MICHEL
</INVENTOR-NAME>
<INVENTOR-NAME>
CHARPENTIER, BRUNO
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Polycyclic aromatic compounds, characterized by
the fact that they correspond to the following general

formula (I):


in which:

R
1
 represents:

(i) a hydrogen atom
(ii) a radical -CH
3
(iii) a radical -CH
2
OH
(iv) a radical -O-R
4
(v) a radical -S(O)t-R
5
(vi) a radical -CO-R
6

R
4
, R
5
, R
6
 and t having the meaning given below,
Ar represents a radical chosen from the radicals of the
following formulae (a)-(i): 



R
4
 and R
8
 having the meaning given below,
R
2
 represents a linear or branched alkyl radical having
1 to 20 carbon atoms or a cycloaliphatic radical,
R
3
 represents:

(a) a radical -X-(CH
2
)
m
-R
10
(b) a radical -(CH
2
)
m
-R
11
(c) a radical -CH=CH-(CH
2
)
n
-R
11
(d) a radical -O- CH
2
-O- CH
2
-CH
2
 -O- CH
3

X, R
10
, R
11
, n and m having the meaning given below,
it being understood that in all that precedes:


R
2
 and R
3
, taken together, can form with the
adjacent naphthalene nucleus a 5- or 6-membered ring

optionally substituted by methyl groups and/or optionally
interrupted by an oxygen atom or by a radical -S(O)z-, z

having the meaning given below:
R
4
 represents a hydrogen atom, an alkyl radical
having 1 to 6 carbon atoms or a radical -(CH
2
)p-(CO)q-R
5
,
p, q and R
5
 having the meaning given below,
R
5
 represents an alkyl radical having 1 to 6
carbon atoms or a heterocycle,
R
6
 represents:

(a) a hydrogen atom
(b) an alkyl radical having 1 to 6 
carbon atoms
(c) a radical of formula:


R' and R'' having the meaning given
below,
(d) a radical -O-R
7
, R
7
 having the
meaning given below,
R
7
 represents a hydrogen atom, a linear or
branched alkyl radical having 1 to 20 carbon atoms, an

alkenyl radical, a mono- or polyhydroxyalkyl radical, an
aryl or aralkyl radical which is (are) optionally substituted

or a sugar residue or an amino acid or peptide
residue,
R
8
 represents a halogen atom, an alkyl radical
having 1 to 6 carbon atoms, a hydroxyl radical, a radical

-OR
9
 or -O-COR
9
, R
9
 having the meaning given below, or alternatively a
hydrogen atom when R
2
 is the 1-adamantyl radical and R
3
 is
different from the -OCH
3
 radical or from the -OH radical,
R
9
 represents an alkyl radical having 1 to 6
carbon atoms,
R
10
 represents a hydrogen atom, an alkyl radical
having 1 to 6 carbon atoms, an aryl radical having 1 to

6 carbon atoms, an aralkyl radical, a monohydroxyalkyl
radical, a polyhydroxyalkyl radical, a radical -CO-R
6
 or
alternatively, but only in the case where m is greater

than or equal to 2, a radical of formula:


R' and R'' having the meaning given below,
R
11
 represents a hydrogen atom, a monohydroxyalkyl
radical, a polyhydroxyalkyl radical, a radical -CO-R
6
, a
radical of formula:


 
R' and R'' having the meaning given below,

or alternatively, but only in the case where m is greater
than or equal to 1, a hydroxyl radical, a radical -OR
9
 or
a radical -O-COR
9
,
R' and R'' represent a hydrogen atom, an alkyl
radical having 1 to 6 carbon atoms, a mono- or polyhydroxyalkyl

radical, an optionally substituted aryl
radical or an amino acid or sugar residue or

alternatively, taken together, form a heterocycle,
X represents an oxygen or sulphur atom,
n is an integer between 0 and 4 inclusive,
m is an integer between 0 and 6 inclusive,
p is an integer between 1 and 3 inclusive,
q is an integer between 0 and 1 inclusive,
t is an integer between 0 and 2 inclusive,
z is an integer between 0 and 2 inclusive,

as well as salts thereof and chiral analogues thereof.
Compounds according to Claim 1, characterized in
that they are in the form of salts of an alkali or

alkaline-earth metal, or alternatively of zinc or of an
organic amine.
Compounds according to one of Claims 1 or 2,
characterized in that the alkyl radicals having 1 to 6

carbon atoms are chosen from the group consisting of
methyl, ethyl, isopropyl, butyl, tert-butyl and hexyl

radicals.
Compounds according to any one of the preceding
claims, characterized in that the linear or branched

alkyl radicals having 1 to 20 carbon atoms are chosen
from the group consisting of methyl, ethyl, propyl, 2-ethylhexyl,

octyl, dodecyl, hexadecyl and octadecyl
radicals.
Compounds according to any one of the preceding
claims, characterized in that the monohydroxyalkyl

radicals are chosen from the group consisting of 2-hydroxyethyl,
2-hydroxypropyl or 3-hydroxypropyl

radicals.
Compounds according to any one of the preceding
claims, characterized in that the polyhydroxyalkyl 

radicals are chosen from the group consisting of 2,3-dihydroxypropyl,
2,3,4-trihydroxybutyl or 2,3,4,5-tetrahydroxypentyl

radicals or the pentaerythritol
residue.
Compounds according to any one of the preceding
claims, characterized in that the aryl radical is a

phenyl radical optionally substituted by at least one
halogen atom, a hydroxyl or a nitro functional group.
Compounds according to any one of the preceding
claims, characterized in that the aralkyl radicals are

chosen from the group consisting of benzyl or phenethyl
radicals optionally substituted by at least one halogen

atom, a hydroxyl or a nitro functional group.
Compounds according to any one of the preceding
claims, characterized in that the alkenyl radicals are

chosen from the group consisting of the radicals
containing 1 to 5 carbon atoms and having one or more

ethylenic unsaturations, in particular the allyl radical.
Compounds according to any one of the preceding
claims, characterized in that the sugar residues are

chosen from the group consisting of glucose, galactose,
mannose or glucuronic acid residues.
Compounds according to any one of the preceding
claims, characterized in that the amino acid residues are

chosen from the group consisting of residues derived from
lysine, glycine or aspartic acid.
Compounds according to any one of the preceding
claims, characterized in that the peptide residues are

chosen from the group consisting of dipeptide or
tripeptide residues.
Compounds according to any one of the preceding
claims, characterized in that the heterocyclic radicals

are chosen from the group consisting of piperidino,
morpholino, pyrrolidino or piperazino radicals which are

optionally substituted at position 4 by a C
1
-C
6
 alkyl
radical or a mono- or polyhydroxyalkyl radical.
Compounds according to any one of the preceding
claims, characterized in that the halogen atoms are

chosen from the group consisting of fluorine, chlorine 
and bromine.
Compounds according to any one of the preceding
claims, characterized in that the cycloaliphatic radicals

are chosen from mono- or polycyclic radicals, in
particular from 1-methylcyclohexyl and 1-adamantyl.
Compounds according to Claim 1, characterized by
the fact that they are chosen from the group consisting

of:

Ethyl 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2anthryl)-4-thiophenecarboxylate,
2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-anthryl)-4-thiophenecarboxylic
acid,
Methyl 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthryl)-2-thiophenecarboxylate,
4-(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-anthryl)-2-thiophenecarboxylic
acid
Ethyl 6-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthryl)nicotinate
6-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-anthryl)nicotinic
acid. 
N-methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthryl)-2-pyrrolecarboxylic
acid,
4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-anthryl)-2-pyrrolecarboxylic
acid,
Methyl 2-hydroxy-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthryl)benzoate,
2-Hydroxy-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthryl)benzoic
acid,
2-Methoxy-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthryl)benzoic

acid,
2-Hydroxy-4-[7-(1-adamantyl)-6-benzyloxy-2-naphthyl]benzoic

acid,
2-Hydroxy-4-[7-(1-adamantyl)-6-hydroxy-2-naphthyl]benzoic

acid,
2-Hydroxy-4-[7-(1-adamantyl)-6-hexyloxy-2-naphthyl]benzoic

acid,
4-[7-(1-Adamantyl)-6-methoxyethoxymethoxy-2-naphthyl]benzoic

acid,
3-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthryl)benzoic 
acid,
N-Propyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthryl)-2-pyrrolecarboxylic
acid,
2-Propyloxy-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthryl)benzoic
acid,
2-Hexyloxy-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthryl)benzoic
acid,
5-[7-(1-Adamantyl)-6-benzyloxy-2-naphthyl]-2-thiophenecarboxylic

acid,
4-[7-(1-Adamantyl)-6-benzyloxy-2-naphthyl]benzoic

acid,
2-Chloro-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthryl)benzoic
acid,
2-Hydroxy-4-[7-(1-adamantyl)-6-(4-fluorobenzyl)oxy-2-naphthyl]benzoic

acid,
2-[7-(1-Adamantyl)-6-hydroxy-2-naphthyl]-4-thiophenecarboxylic

acid,
Methyl 4-[7-(1-adamantyl)-6-benzyloxycarbonyl-2-naphthyl]benzoate.
Compounds according to Claim 1, characterized in
that Ar represents a radical of formula (a) or (i), R
6

represents a radical -OR
7
, R
7
 having the meaning given
above, and R
2
 and R
3
, taken together, form with the
adjacent naphthalene nucleus a 6-membered ring

substituted by methyl groups.
Compounds according to any one of the preceding
claims, for use as medicinal products.
Compounds according to Claim 18, for use as
medicinal products intended for the treatment of

dermatological, rheumatic, respiratory, cardiovascular
and ophthalmological conditions.
Use of at least one of the compounds defined in
Claims 1 to 17 for the manufacture of a medicinal product

intended for the treatment of dermatological, rheumatic,
respiratory, cardiovascular and ophthalmological

conditions.
Pharmaceutical composition, characterized by the
fact that it comprises, in a pharmaceutically acceptable 

carrier, at least one of the compounds as defined in any
one of Claims 1 to 17.
Composition according to Claim 21, characterized
in that the concentration of compound(s) according to one

of Claims 1 to 17 is between 0.001 % and 5 % by weight
relative to the whole composition.
Cosmetic composition, characterized by the fact
that it comprises, in a cosmetically acceptable carrier,

at least one of the compounds as defined in any one of
Claims 1 to 17.
Composition according to Claim 23, characterized
in that the concentration of compound(s) according to one

of Claims 1 to 17 is between 0.001 % and 3 % by weight
relative to the whole composition.
Use of a cosmetic composition as defined in one
of Claims 23 or 24 for body or hair care.
</CLAIMS>
</TEXT>
</DOC>
